bicalutamide has been researched along with ridaforolimus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clackson, T; Miller, D; Rivera, VM; Squillace, RM; Wang, F; Wardwell, SD | 1 |
| de Bono, JS; de Wit, R; Ebbinghaus, SW; Heath, KH; Hudes, GR; Li, X; Meulenbeld, HJ; Tagawa, ST; Whang, YE; Zandvliet, AS | 1 |
1 trial(s) available for bicalutamide and ridaforolimus
| Article | Year |
|---|---|
Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC).
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Interactions; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Nitriles; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Sirolimus; TOR Serine-Threonine Kinases; Tosyl Compounds | 2013 |
1 other study(ies) available for bicalutamide and ridaforolimus
| Article | Year |
|---|---|
Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models.
Topics: Androgen Receptor Antagonists; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Male; Mice; Mice, Nude; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; PTEN Phosphohydrolase; Receptors, Androgen; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tosyl Compounds; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |